Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31278969 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CA12MMP2CA9CA14 | |
| SCHEMBL873030 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CA12MMP2CA9CA14 | |
| SCHEMBL30546709 | 0.85 | ALDH1A1 (0.58) | ALDH1A1CA12MMP2CA9CA14 | |
| SCHEMBL21635117 | 0.83 | MTOR (0.50) | ALDH1A1CA12MMP2CA9CA14 | |
| SCHEMBL17263871 | 0.83 | ALDH1A1 (0.53) | ALDH1A1CA12MMP2CA9CA14 | |
| SCHEMBL11200107 | 0.83 | MMP2 (0.51) | ALDH1A1CA12MMP2CA9CA14 | |
| SCHEMBL11200102 | 0.83 | MMP2 (0.51) | ALDH1A1CA12MMP2CA9CA14 | |
| SCHEMBL28885515 | 0.82 | MMP2 (0.57) | ALDH1A1CA12MMP2CA9CA14 | |
| SCHEMBL29018813 | 0.82 | ALDH1A1 (0.62) | ALDH1A1CA12MMP2CA9CA14 | |
| SCHEMBL3663092 | 0.82 | SLC6A3 (0.43) | ALDH1A1MTORKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3374520-A1 | BIOSENSORS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-09-19 | — | — | EP | claimed |
| WO-2017081684-A1 | BIOSENSORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-05-18 | — | — | WO | claimed |
| US-20090023661-A1 | Use of Antagonists of the Bradykinin B2 Receptor for the Treatment of Osteoarthrosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2009-01-22 | — | — | US | claimed |
| US-20040248809-A1 | Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-09 | — | — | US | claimed |
| US-12428455-B2 | Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250223328-A1 | TRUNCATED DOMINANT NEGATIVE CEBPB AND CEBPD PROTEINS AND METHODS OF USE FOR DECREASING VIABILITY OF NEOPLASTIC CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-07-10 | — | — | US | disclosed |
| CN-113396218-B | Engineered transaminase polypeptides | 科德克希思公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024086775-A2 | TRUNCATED DOMINANT NEGATIVE CEBPB AND CEBPD PROTEINS AND METHODS OF USE FOR DECREASING VIABILITY OF NEOPLASTIC CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20210163551-A1 | DOMINANT NEGATIVE CEBPB AND CEBPD PROTEINS AND METHODS OF USE FOR DECREASING VIABILITY OF NEOPLASTIC CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-06-03 | — | — | US | disclosed |
| WO-2020033555-A2 | DOMINANT NEGATIVE CEBPB AND CEBPD PROTEINS AND METHODS OF USE FOR DECREASING VIABILITY OF NEOPLASTIC CELLS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-02-13 | — | — | WO | disclosed |
| CN-110078811-A | A kind of polypeptide IMB-P1 with anti-tumor activity and its application | 中国医学科学院医药生物技术研究所 | 2019-08-02 | — | — | CN | disclosed |
| US-20190201349-A1 | CAPSULES AND PARTICLES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-07-04 | — | — | US | disclosed |
| EP-0663897-B1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | AKZO NOBEL NV (NL) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996011894-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | AKZO NOBEL N.V. (NL) | 1996-04-25 | — | — | WO | disclosed |
| EP-0663897-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE. | AKZO NOBEL NV (NL) | 1995-07-26 | — | — | EP | disclosed |
| EP-0093611-B2 | Composite plasmid | AJINOMOTO KK (JP) | 1995-03-22 | — | — | EP | disclosed |
| WO-1994007814-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | AKZO NOBEL N.V. (NL) | 1994-04-14 | — | — | WO | disclosed |
| EP-0093611-B1 | COMPOSITE PLASMID | AJINOMOTO CO., INC. (JP) | 1987-07-22 | — | — | EP | disclosed |
| US-4514502-A | DRUG RESISTANCE | AJINOMOTO CO., INC. (JP) | 1985-04-30 | — | — | US | disclosed |
| EP-0093611-A1 | Composite plasmid | AJINOMOTO CO., INC. (JP) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201349-A1 | CAPSULES AND PARTICLES AND USES THEREOF | ALG1, LPO, FUT5 | ALDH1A1 1287/4885CA12 322/4885MMP2 412/4885 |
| US-20040248809-A1 | Use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis | BDKRB2, BDKRB1, PLAT | ALDH1A1 3652/4885CA12 3446/4885MMP2 106/4885 |
| US-20090023661-A1 | Use of Antagonists of the Bradykinin B2 Receptor for the Treatment of Osteoarthrosis | BDKRB2, BDKRB1, PLAT | ALDH1A1 3733/4885CA12 3504/4885MMP2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.